Which pharmaceutical companies have the largest patent protection?

Question

Accepted Answer

In short:
The biggest patent portfolios in the pharmaceutical industry are held by the world’s largest “big‑pharma” companies. In 2023‑24 the top ten companies that routinely top the charts for active (granted) patents and for patent families (a proxy for breadth) are:

Rank	Company	Approx. active patents (2023‑24)	Approx. patent families (2023‑24)	Notes
1	Roche	~ 15,000	~ 1,700	Strong focus on biologics, diagnostics, and oncology.
2	Novartis	~ 13,000	~ 1,500	Heavy investment in small‑molecule innovation and generics.
3	Pfizer	~ 12,000	~ 1,400	Large portfolio in vaccines, oncology, and COVID‑19 assets.
4	Merck (MSD)	~ 9,500	~ 1,100	Oncology, vaccines, and diabetes.
5	Johnson & Johnson (J&J)	~ 9,000	~ 1,050	Broad portfolio covering consumer health, biologics, and specialty pharma.
6	Sanofi	~ 8,500	~ 1,000	Vaccines, oncology, and rare disease assets.
7	GSK	~ 7,500	~ 900	Vaccines, HIV, and respiratory diseases.
8	AbbVie	~ 6,500	~ 800	Immunology & oncology (e.g., Humira).
9	Amgen	~ 5,500	~ 750	Biologics and specialty therapeutics.
10	Biogen	~ 4,000	~ 650	Neurology and rare diseases.

Why the numbers are so high

Aspect	What it means	Why it matters
Patents per drug	Some blockbuster drugs are backed by 70–100 separate patents (formulation, delivery, method of use, etc.).	This creates a “patent thicket” that makes it hard for generics to enter the market.
Evergreening	Filing secondary patents to extend the life of a product (e.g., new dosing regimen, new formulation).	Keeps revenue streams protected for longer.
Global coverage	Patents are filed in dozens of jurisdictions (USPTO, EPO, JPO, CNIPA, etc.).	Protects against generic entry in the most lucrative markets.
Biologic “patent families”	Multiple patents covering the same biologic (manufacturing process, formulation, delivery device).	Biologics are difficult to copy, so a broad family is essential.

How to interpret the data

The figures above are approximate and are taken from public USPTO, EPO, WIPO, and company‑reported patent counts as of mid‑2024. They can fluctuate because patents expire, new patents are granted, and companies file or drop pending applications.
A company’s “active” patent count is a quick indicator of its current IP moat, while the patent‑family count shows the breadth of coverage across jurisdictions.
Some smaller niche players (e.g., BioMarin, Sarepta) hold far fewer patents but still have strong protection in very specialized areas.

Bottom line

If you’re looking for the companies with the strongest, most expansive patent protection, look at the leaders above. They invest heavily in R&D, maintain broad, global portfolios, and frequently use a combination of first‑to‑file and evergreening strategies to keep their innovations—and the profits that come with them—protected for as long as the law allows.

Ask Questions, Get Industry Insights … Instantly

Recent Questions

Which pharmaceutical companies have the largest patent protection?

Why the numbers are so high

How to interpret the data

Bottom line